Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for ...

Pain is easy to understand until it isn’t. A stubbed toe or sprained ankle hurts, but it makes sense because the cause is ...

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD compared with SGLT-2 inhibitors.

Parkinson’s disease (PD), the second most prevalent neurodegenerative disorder worldwide, is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra, leading to a ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

DelveInsight’s Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline ...

The National Cancer Center Research Institute in Tokyo reports that a newly isolated gut bacterium, designated ...

In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher risk of developing gastroesophageal reflux disease and ...

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...